US based Kemin Industries, a global ingredient manufacturer that strives to sustainably transform the quality of life every day for 80 percent of the world with its products and services, has signed an exclusive agreement with US and Hong Kong based Pacific GeneTech (PGT), a biologics company that develops and commercializes next-generation vaccines for areas of high unmet or underserved needs in food safety and animal health, to license PGT's Salmonella vaccine for poultry.
PGT's Salmonella vaccine addresses multiple serovars of Salmonella. It was developed from the company's proprietary Aegis platform, which is applicable to multiple pathogens, including bacteria, parasites and viruses. Both the platform and Salmonella vaccine were originally developed by the University of Arkansas's Poultry Health Laboratory, in collaboration with other U.S. and Canadian universities and with support from the United States Department of Agriculture and the Arkansas Economic Development Commission.
"Partnering with PGT on this vaccine will allow Kemin to deliver the technology needed to address Salmonella contamination in poultry, a common pathogen that threatens food safety and the health of consumers," said Dr. Chris Nelson, President and CEO, Kemin. "I am thrilled that we will be able to bring this vaccine to market around the world. This will make the vaccine more accessible which, in turn, may help reduce the incidence rate of Salmonella in consumer poultry products."
As part of its partnership with PGT, Kemin will focus on developing the Salmonella vaccine and registering it in the United States and other countries, beginning with the European Union. Kemin will also begin expanding the Salmonella vaccine's availability in Southeast Asia and Africa.